Efficacies and Chemical Structures of Modern Drugs for Hepatitis C Virus Treatment


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Hepatitis C virus (HCV) is the leading cause of chronic liver disease, surpassing hepatitis B virus and alcohol. The paradigm for treating HCV has radically changed over the last 20 years. The tolerability and duration of treating HCV patients was altered fundamentally by the emergence of modern and more efficacious treatment regimens and plans. Nevertheless, the risk of developing serious adverse reactions, including those due to drug–drug interactions, remains high. Currently, eight drugs are approved for treating HCV and avoid the use of interferons. The present article reviews these drugs with respect to their efficacy and safety for use in patients with various HCV genotypes.

Sobre autores

A. Kazakov

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Autor responsável pela correspondência
Email: a.kazakov15@gmail.com
Rússia, 8/2 Petrovskii Blvd, Moscow, 127051

V. Lepakhin

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: a.kazakov15@gmail.com
Rússia, 8/2 Petrovskii Blvd, Moscow, 127051

T. Bukatina

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: a.kazakov15@gmail.com
Rússia, 8/2 Petrovskii Blvd, Moscow, 127051

I. Snegireva

Scientific Centre for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation

Email: a.kazakov15@gmail.com
Rússia, 8/2 Petrovskii Blvd, Moscow, 127051

K. Zatolochina

Peoples Friendship University of Russia

Email: a.kazakov15@gmail.com
Rússia, Moscow, 117198

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Springer Science+Business Media, LLC, part of Springer Nature, 2018